Drugs / SARS-CoV-2 mRNA vaccine formulation 1
SARS-CoV-2 mRNA vaccine formulation 1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04798027 | Mar 2021 → Jun 2022 | COVID-19 | Sanofi Pasteur, a Sanofi Company | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SARS-CoV-2 mRNA vaccine formulation 1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04798027 ↗ |
| Modality | Messenger RNA (mRNA) | “SARS-CoV-2 mRNA vaccine formulation 1” NCT04798027 ↗ |